EP0440147A3 - Preparation and use of a human antibody gene bank (human antibody libraries) - Google Patents
Preparation and use of a human antibody gene bank (human antibody libraries) Download PDFInfo
- Publication number
- EP0440147A3 EP0440147A3 EP19910101095 EP91101095A EP0440147A3 EP 0440147 A3 EP0440147 A3 EP 0440147A3 EP 19910101095 EP19910101095 EP 19910101095 EP 91101095 A EP91101095 A EP 91101095A EP 0440147 A3 EP0440147 A3 EP 0440147A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- human antibody
- preparation
- human
- cdna
- gene bank
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04008412A EP1566442B1 (en) | 1990-02-01 | 1991-01-28 | Preparation and use of a human antibody gene bank (human antibody libraries) |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4002898A DE4002898A1 (en) | 1990-02-01 | 1990-02-01 | Human antibody library |
DE4002898 | 1990-02-01 | ||
DE4003881A DE4003881A1 (en) | 1990-02-09 | 1990-02-09 | Human antibody library |
DE4003881 | 1990-02-09 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04008412A Division EP1566442B1 (en) | 1990-02-01 | 1991-01-28 | Preparation and use of a human antibody gene bank (human antibody libraries) |
EP04008412A Division-Into EP1566442B1 (en) | 1990-02-01 | 1991-01-28 | Preparation and use of a human antibody gene bank (human antibody libraries) |
EP04008412.1 Division-Into | 2004-04-07 |
Publications (4)
Publication Number | Publication Date |
---|---|
EP0440147A2 EP0440147A2 (en) | 1991-08-07 |
EP0440147A3 true EP0440147A3 (en) | 1992-07-08 |
EP0440147B1 EP0440147B1 (en) | 2004-09-22 |
EP0440147B2 EP0440147B2 (en) | 2014-05-14 |
Family
ID=25889602
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91101095.7A Expired - Lifetime EP0440147B2 (en) | 1990-02-01 | 1991-01-28 | Preparation and use of a human antibody gene bank (human antibody libraries) |
EP04008412A Expired - Lifetime EP1566442B1 (en) | 1990-02-01 | 1991-01-28 | Preparation and use of a human antibody gene bank (human antibody libraries) |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04008412A Expired - Lifetime EP1566442B1 (en) | 1990-02-01 | 1991-01-28 | Preparation and use of a human antibody gene bank (human antibody libraries) |
Country Status (12)
Country | Link |
---|---|
US (1) | US6319690B1 (en) |
EP (2) | EP0440147B2 (en) |
JP (1) | JP3514778B2 (en) |
KR (1) | KR100186823B1 (en) |
AT (2) | ATE449853T1 (en) |
AU (1) | AU633682B2 (en) |
CA (1) | CA2035381C (en) |
DE (2) | DE59109273D1 (en) |
DK (1) | DK0440147T3 (en) |
ES (2) | ES2225816T5 (en) |
IE (1) | IE910335A1 (en) |
PT (1) | PT96625B (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0440147T3 (en) † | 1990-02-01 | 2005-01-17 | Dade Behring Marburg Gmbh | Preparation and use of human antibody gene banks ("human antibody libraries") |
IE922287A1 (en) * | 1991-07-15 | 1993-01-27 | Wellcome Found | Production of antibodies |
DE4142077A1 (en) * | 1991-12-19 | 1993-06-24 | Boehringer Mannheim Gmbh | METHOD FOR EXPRESSING RECOMBINANT ANTIKOERPERS |
AU1736495A (en) * | 1994-01-31 | 1995-08-15 | Trustees Of Boston University | Polyclonal antibody libraries |
DE19728697C1 (en) * | 1997-07-04 | 1999-03-25 | Deutsches Krebsforsch | Human antibody against a fusion (poly) peptide or protein which contains at least six histidines |
AU9148498A (en) * | 1997-09-19 | 1999-04-12 | Medleys Laboratories Inc. | Method and kit for early diagnosis of autoimmunity and lymphoma in central nervous system |
US7270969B2 (en) * | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
US6994982B1 (en) * | 1999-05-05 | 2006-02-07 | Phylogica Limited | Isolating biological modulators from biodiverse gene fragment libraries |
US7803765B2 (en) * | 1999-05-05 | 2010-09-28 | Phylogica Limited | Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom |
EP2199393B1 (en) * | 2000-04-17 | 2012-10-31 | Dyax Corp. | Methods of constructing display libraries of genetic packages for members of a diverse family of peptides |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
JP4860098B2 (en) | 2000-12-18 | 2012-01-25 | ダイアックス、コープ | Library focused on genetic packaging |
WO2003035842A2 (en) * | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
CA2553692C (en) | 2004-01-20 | 2014-10-07 | Kalobios, Inc. | Antibody specificity transfer using minimal essential binding determinants |
US20050282233A1 (en) * | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
WO2005119244A1 (en) * | 2004-06-03 | 2005-12-15 | Phylogica Limited | Peptide modulators of cellular phenotype and bi-nucleic acid fragment library |
PL1974020T3 (en) * | 2005-12-16 | 2011-11-30 | Ribovax Biotechnologies Sa | Methods for obtaining immortalized antibody secreting cells |
ES2683846T3 (en) | 2006-01-20 | 2018-09-28 | Cell Signaling Technology, Inc. | ROS mutant and translocation kinase in human non-small cell lung carcinoma |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
US8575070B2 (en) * | 2006-02-20 | 2013-11-05 | Phylogica Limited | Methods of constructing and screening libraries of peptide structures |
ES2561406T3 (en) | 2006-04-14 | 2016-02-26 | Cell Signaling Technology, Inc. | ALK gene and kinase mutant defects in solid human tumors |
AU2007299562A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor |
EP2170932A4 (en) * | 2007-06-20 | 2012-10-10 | Phylogica Ltd | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith |
EP3753947A1 (en) | 2007-09-14 | 2020-12-23 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP3072963B1 (en) | 2007-10-18 | 2020-04-01 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
US9873957B2 (en) | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
CA2968164C (en) | 2008-04-24 | 2019-08-20 | Dyax Corp. | Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs |
PL2881402T3 (en) | 2009-02-12 | 2017-10-31 | Cell Signaling Technology Inc | Mutant ROS expression in human liver cancer |
AU2010291902A1 (en) * | 2009-09-14 | 2012-04-05 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
WO2011084605A1 (en) * | 2009-12-16 | 2011-07-14 | The Trustees Of The University Of Pennsylvania | Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same |
MX360336B (en) | 2010-07-16 | 2018-10-30 | Adimab Llc Star | Antibody libraries. |
US20120101108A1 (en) | 2010-08-06 | 2012-04-26 | Cell Signaling Technology, Inc. | Anaplastic Lymphoma Kinase In Kidney Cancer |
EP3103810A3 (en) | 2011-04-21 | 2017-03-08 | Garvan Institute of Medical Research | Modified variable domain molecules and methods for producing and using them |
ES2655842T3 (en) | 2012-04-18 | 2018-02-21 | Cell Signaling Technology, Inc. | EGFR and ROS1 in cancer |
WO2015184321A2 (en) * | 2014-05-29 | 2015-12-03 | Siemens Healthcare Diagnostics Inc. | Rare molecule detection |
NZ760841A (en) | 2017-07-11 | 2024-02-23 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
AU2019379576A1 (en) | 2018-11-13 | 2021-06-03 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014430A1 (en) * | 1989-05-16 | 1990-11-29 | Scripps Clinic And Research Foundation | A new method for tapping the immunological repertoire |
WO1991010737A1 (en) * | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2919890B2 (en) † | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
CA2016841C (en) † | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
DK0440147T3 (en) † | 1990-02-01 | 2005-01-17 | Dade Behring Marburg Gmbh | Preparation and use of human antibody gene banks ("human antibody libraries") |
-
1991
- 1991-01-28 DK DK91101095T patent/DK0440147T3/en active
- 1991-01-28 AT AT04008412T patent/ATE449853T1/en not_active IP Right Cessation
- 1991-01-28 DE DE59109273T patent/DE59109273D1/en not_active Expired - Lifetime
- 1991-01-28 EP EP91101095.7A patent/EP0440147B2/en not_active Expired - Lifetime
- 1991-01-28 DE DE59109264T patent/DE59109264D1/en not_active Expired - Lifetime
- 1991-01-28 AT AT91101095T patent/ATE277179T1/en not_active IP Right Cessation
- 1991-01-28 ES ES91101095.7T patent/ES2225816T5/en not_active Expired - Lifetime
- 1991-01-28 EP EP04008412A patent/EP1566442B1/en not_active Expired - Lifetime
- 1991-01-28 ES ES04008412T patent/ES2336444T3/en not_active Expired - Lifetime
- 1991-01-31 CA CA002035381A patent/CA2035381C/en not_active Expired - Lifetime
- 1991-01-31 IE IE033591A patent/IE910335A1/en not_active IP Right Cessation
- 1991-01-31 AU AU70113/91A patent/AU633682B2/en not_active Expired
- 1991-01-31 PT PT96625A patent/PT96625B/en not_active IP Right Cessation
- 1991-02-01 KR KR1019910001733A patent/KR100186823B1/en not_active IP Right Cessation
- 1991-02-01 JP JP03221591A patent/JP3514778B2/en not_active Expired - Lifetime
-
1993
- 1993-05-06 US US08/057,430 patent/US6319690B1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014430A1 (en) * | 1989-05-16 | 1990-11-29 | Scripps Clinic And Research Foundation | A new method for tapping the immunological repertoire |
WO1991010737A1 (en) * | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
Non-Patent Citations (1)
Title |
---|
WINTER G., MILSTEIN C.: "MAN-MADE ANTIBODIES.", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 349., 24 January 1991 (1991-01-24), United Kingdom, pages 293 - 299., XP000572614, ISSN: 0028-0836, DOI: 10.1038/349293a0 * |
Also Published As
Publication number | Publication date |
---|---|
ATE277179T1 (en) | 2004-10-15 |
EP1566442A3 (en) | 2006-06-07 |
ATE449853T1 (en) | 2009-12-15 |
PT96625B (en) | 1998-07-31 |
AU633682B2 (en) | 1993-02-04 |
IE910335A1 (en) | 1991-08-14 |
AU7011391A (en) | 1991-08-08 |
CA2035381A1 (en) | 1991-08-02 |
CA2035381C (en) | 2004-11-09 |
EP0440147B1 (en) | 2004-09-22 |
ES2225816T3 (en) | 2005-03-16 |
EP1566442B1 (en) | 2009-11-25 |
DK0440147T3 (en) | 2005-01-17 |
EP1566442A2 (en) | 2005-08-24 |
DE59109264D1 (en) | 2004-10-28 |
US6319690B1 (en) | 2001-11-20 |
ES2336444T3 (en) | 2010-04-13 |
JPH04211394A (en) | 1992-08-03 |
KR910021475A (en) | 1991-12-20 |
ES2225816T5 (en) | 2014-08-21 |
PT96625A (en) | 1991-11-29 |
EP0440147A2 (en) | 1991-08-07 |
KR100186823B1 (en) | 1999-04-01 |
JP3514778B2 (en) | 2004-03-31 |
DE59109273D1 (en) | 2010-01-07 |
EP0440147B2 (en) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0440147A3 (en) | Preparation and use of a human antibody gene bank (human antibody libraries) | |
Schaniel et al. | Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells | |
US5627052A (en) | Methods for the production of proteins with a desired function | |
Ausiello et al. | CD38 ligation induces discrete cytokine mRNA expression in human cultured lymphocytes | |
EP1555328A3 (en) | Recombinant library screening methods | |
CA2035384A1 (en) | Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries") | |
CA2344086A1 (en) | Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof | |
Li et al. | Lymphocytes infiltrating human ovarian tumors: Synergy between tumor necrosis factor α and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes | |
Gouttefangeas et al. | The CD39 molecule defines distinct cytotoxic subsets within alloactivated human CD8‐positive cells | |
EP2221384A1 (en) | Method for production of antibody | |
Nakano et al. | Identification of intrathymic T progenitor cells by expression of Thy‐1, IL 2 receptor and CD3 | |
CN111417719B (en) | B cell culture method | |
Epperson et al. | In vitro T‐cell receptor Vβ repertoire analysis may identify which T‐cell Vβ families mediate graft‐versus‐leukaemia and graft‐versus‐host responses after human leucocyte antigen‐matched sibling stem cell transplantation | |
Clémenceau et al. | Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy | |
Johnson et al. | Destructive Interactions Between Murine Macrophages, Tumor Cells, and Antibodies of the IgG 2a Isotype | |
Hattori et al. | Generation of continuous large granular lymphocyte lines by interleukin 2 from the spleen cells of mice infected with Moloney leukemia virus. Involvement of interleukin 3. | |
Yang et al. | Differential expression of novel genes by bone marrow-derived macrophage populations | |
CA2084521A1 (en) | Hepatitis c virus antigen polypeptide, production method therefor, and antibody detection method | |
Iho et al. | IL-6 enhances the cytotoxic activity of thymocyte-derived CD56+ cells | |
US20010053523A1 (en) | Method for identification of biologically active peptides and nucleic acids | |
De Wildt et al. | Isolation and Characterization of single AntiOU1A-specific B Cells from Autoimmune patients. | |
WO1994011507A3 (en) | Production of monoclonal recombinant antibodies without the use of hybridomas by in vitro spleen fragment culture combined with isothermal self-sustained sequence replication of rna | |
Gaweco et al. | Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression | |
Leclercq et al. | Direct Evidence for Partial Target Specificity in Lymphokine‐Activated Killer Thymocytes | |
Takemura et al. | Functional Fv fragment of an antibody specific for CD28: Fv‐mediated co‐stimulation of T cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19930104 |
|
17Q | First examination report despatched |
Effective date: 19940511 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEHRING DIAGNOSTICS GMBH |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DADE BEHRING MARBURG GMBH |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12Q 1/68 B Ipc: 7G 01N 33/53 B Ipc: 7C 12P 21/08 B Ipc: 7C 12N 15/13 A |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 59109264 Country of ref document: DE Date of ref document: 20041028 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20040403935 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20050116 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2225816 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLAQ | Examination of admissibility of opposition: information related to despatch of communication + time limit deleted |
Free format text: ORIGINAL CODE: EPIDOSDOPE2 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLBQ | Unpublished change to opponent data |
Free format text: ORIGINAL CODE: EPIDOS OPPO |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: CRUCELL HOLLAND B.V. Effective date: 20050621 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: CRUCELL HOLLAND B.V. |
|
PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
APBP | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2O |
|
APAH | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNO |
|
APBQ | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3O |
|
APAL | Date of receipt of statement of grounds of an appeal modified |
Free format text: ORIGINAL CODE: EPIDOSCNOA3O |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH |
|
NLT2 | Nl: modifications (of names), taken from the european patent patent bulletin |
Owner name: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH Effective date: 20081015 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH Free format text: DADE BEHRING MARBURG GMBH#POSTFACH 11 49#35001 MARBURG (DE) -TRANSFER TO- SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH#EMIL-VON-BEHRING-STRASSE 76#35041 MARBURG (DE) Ref country code: CH Ref legal event code: NV Representative=s name: SIEMENS SCHWEIZ AG |
|
NLT1 | Nl: modifications of names registered in virtue of documents presented to the patent office pursuant to art. 16 a, paragraph 1 |
Owner name: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: CD |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20100222 Year of fee payment: 20 Ref country code: LU Payment date: 20100114 Year of fee payment: 20 Ref country code: DK Payment date: 20100112 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20100127 Year of fee payment: 20 Ref country code: FR Payment date: 20100211 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20100204 Year of fee payment: 20 Ref country code: AT Payment date: 20091228 Year of fee payment: 20 Ref country code: GB Payment date: 20100115 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20100325 Year of fee payment: 20 Ref country code: NL Payment date: 20100118 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20100408 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20100112 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20100115 Year of fee payment: 20 |
|
BE20 | Be: patent expired |
Owner name: *DADE BEHRING MARBURG G.M.B.H. Effective date: 20110128 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20110127 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20110224 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110129 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110127 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V4 Effective date: 20110128 |
|
APBU | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9O |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110128 |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
27A | Patent maintained in amended form |
Effective date: 20140514 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R102 Ref document number: 59109264 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R102 Ref document number: 59109264 Country of ref document: DE Effective date: 20140514 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: DC2A Ref document number: 2225816 Country of ref document: ES Kind code of ref document: T5 Effective date: 20140821 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20140826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140815 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140514 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: MA Ref document number: 20040403935 Country of ref document: GR Effective date: 20110129 |